We recently demonstrated that inhaled IFN-γ in IPF patients is safe with no systemic side effects, an effect very different from that of systemic IFN-γ, which causes generalized systemic side effects [21]. The gene discussed is IFNG; the disease is idiopathic pulmonary fibrosis.